Skip to main content
 

We are developing a robust pipeline of therapeutics that target the dynamic interaction between the human GI barrier, and certain species of microbiota within the microbiome. We are currently working in multiple therapeutic areas, including gastrointestinal diseases, neurological disorders, and other immunomodulated diseases.

Please contact us to learn more.